Updated: Jun 30, 2008
Corneal foreign body is foreign material on or in the cornea, usually metal, glass, or organic material.
Corneal foreign bodies generally fall under the category of minor ocular trauma. Small particles may become lodged in the corneal epithelium or stroma, particularly when projected toward the eye with considerable force.
The foreign object may set off an inflammatory cascade, resulting in dilation of the surrounding vessels and subsequent edema of the lids, conjunctiva, and cornea. White blood cells also may be liberated, resulting in an anterior chamber reaction and/or corneal infiltration. If not removed, a foreign body can cause infection and/or tissue necrosis.
Foreign bodies are one of the most frequent causes of visits for ophthalmic emergencies. Sometimes, the foreign body may not be present at the time of examination, having left the residual corneal abrasion with resultant pain.
Superficial corneal foreign bodies are much more common than deeply embedded corneal foreign bodies. The possibility of an intraocular foreign body must always be considered when a patient presents with a history of trauma.
In major league baseball, 33% of all eye injuries are corneal abrasions; in the National Basketball Association, corneal abrasions account for 12% of all eye traumas.
No difference in frequency is observed internationally.
Generally, superficial foreign bodies that are removed soon after the injury leave no permanent sequelae. However, corneal scarring or infection may occur. The longer the time interval between the injury and treatment, the greater the likelihood of complications.
If the foreign body fully penetrates into the anterior or posterior chambers, then it is officially an intraocular foreign body. In this case, eye morbidity is much more common. Damage to the iris, lens, and retina can occur and severely damage vision. Any intraocular foreign body can lead to infection and endophthalmitis, a serious condition possibly leading to loss of the eye.
Similar to other traumatic injuries, the incidence in males is much higher than in females.
Similar to most other traumatic injuries, the peak incidence is found in the second decade and generally occurs in people younger than 40 years.
The activities of the patient and their surroundings are important. The time and the place of the injury, along with exactly how it occurred, are important. For example, a patient who was working with a high-speed grinding machine is likely to have an intraocular foreign body that may be occult in nature, whereas a patient who was working underneath a car when rust fell gently on the eye is likely to have only an external injury.
Corneal foreign body injury can occur just about anywhere. They commonly occur both at home and at work.
Corneal Abrasion
Foreign Body, Intraocular
Keratitis, Bacterial
Keratitis, Fungal
Any eye after trauma, especially with a foreign body, needs to be evaluated for a ruptured globe and an intraocular foreign body.
Consider the possibility of an underlying corneal sensation problem. In this setting, corneal abrasions may heal poorly and may recur easily if a problem exists with corneal sensation. See Keratopathy, Neurotrophic.
Management objectives include relieving pain, avoiding infection, and preventing permanent loss of function.
An uncomplicated case in which the foreign body is removed can be treated with standard antibiotics. If a large epithelial defect is present, an antibiotic ointment is placed prior to the use of a patch. Complicated cases should be seen by an ophthalmologist immediately and prior to any therapy. For example, if an infiltrate is present, the ophthalmologist may want to scrape and plate the lesion before any antibiotic is instilled in the eye.
Prevent infection of an open corneal abrasion.
For ocular infections, involving cornea or conjunctiva, resulting from strains of microorganisms susceptible to this antibiotic. Available as a solution and ointment. Trimethoprim and polymyxin B are rarely sensitizing, and they have a wide spectrum of action in combination.
Gram-positive: S aureus, S epidermidis, Streptococcus species (group A beta-hemolytic and nonhemolytic), S pneumoniae
Gram-negative: P aeruginosa, H influenzae, H aegyptius, E coli, K pneumoniae, P mirabilis (indole-positive), Proteus species (indole-negative), E aerogenes, C freundii, C diversus, A calcoaceticus, M lacunata (some strains), S marcescens
1 gtt qid
<2 months: Not established
>2 months: 1 gtt qid
None reported
Documented hypersensitivity; viral, fungal, and mycobacterial infections of the eye
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Do not use in deep ocular infections or in those likely to become systemic; prolonged use of antibiotics or repeated therapy may result in bacterial or fungal overgrowth of nonsusceptible organism; if redness, irritation, swelling, or pain persists or increases, discontinue use immediately and reevaluate therapy; patient should avoid contamination of the dropper
Like other aminoglycosides, the bactericidal activity of tobramycin is accomplished by specific inhibition of normal protein synthesis in susceptible bacteria, but very little presently is known about this action. May inhibit bacterial mRNA synthesis, causing inhibition of bacterial growth.
1 gtt qid
Administer as in adults
Effects of this drug are decreased when used concurrently with gentamicin
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Do not use in deep-seated ocular infections or in those that may become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms
Pyridine carboxylic acid derivative with broad-spectrum bactericidal effect.
1 gtt qid
Administer as in adults
None reported
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Do not use in ocular infections that may become systemic; superinfections may occur with prolonged or repeated antibiotic therapy
Inhibits bacterial growth by inhibiting DNA gyrase.
0.5-inch ribbon in subconjunctival sac qid
Administer as in adults
None reported
Documented hypersensitivity; viral, mycobacterial, and fungal eye infections; avoid coadministration with steroid combinations after uncomplicated removal of a foreign body from cornea
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
A white crystalline precipitate located in superficial portion of corneal defect may occur (onset starts in 1-7 d); precipitate usually is cleared within 2 wk and does not adversely affect clinical course or outcome; do not use in ocular infections that may become systemic; superinfections may occur with prolonged or repeated antibiotic therapy
Prevents transfer of mucopeptides into growing cell wall, inhibiting bacterial growth.
0.5-inch ribbon in subconjunctival sac qid
Administer as in adults
None reported
Documented hypersensitivity; vaccinia, varicella, epithelial herpes simplex keratitis, mycobacterial infections, and fungal diseases of the eye; patients using steroid combinations after uncomplicated removal of a corneal foreign body
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Ophthalmic ointments may delay healing of corneal epithelia; in deep-seated infections of the eye, supplement with systemic medications; prolonged use may result in overgrowth of nonsusceptible organisms
Fourth-generation fluoroquinolone ophthalmic indicated for bacterial conjunctivitis. Elicits a dual mechanism of action by possessing an 8-methoxy group, thereby inhibiting the enzymes DNA gyrase and topoisomerase IV. DNA gyrase is involved in bacterial DNA replication, transcription, and repair. Topoisomerase IV is essential in chromosomal DNA partitioning during bacterial cell division. Indicated for bacterial conjunctivitis due to Corynebacterium propinquum, S aureus, Staphylococcus epidermidis, Streptococcus mitis, S pneumoniae, or H influenzae.
Days 1-2: Instill 1 gtt into affected eye(s) q2h while awake; not to exceed 8 administrations/d
Days 3-7: Instill 1 gtt into affected eye(s) up to 4 times/d while awake
<1 year: Not established
>1 year: Administer as in adults
None reported
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
For ophthalmic use only; commonly causes conjunctival irritation, increased lacrimation, corneal inflammation, or papillary conjunctivitis; less common adverse effects include conjunctival hemorrhage, dry eye, eye discharge, eye irritation, eye pain, eyelid swelling, headache, red eye, reduced visual acuity, or taste disturbance
For comfort of the eye and to prevent iris adhesion in cases of traumatic iritis.
Cyclopentolate is an anticholinergic agent that induces relaxation of the sphincter of the iris and ciliary muscles. When applied topically to the eyes, it causes rapid, intense cycloplegic and mydriatic effects that reach a peak in 15-60 min; recovery usually occurs within 24 h. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises.
1 gtt qd/tid
Administer as in adults
Decreases effects of carbachol and cholinesterase inhibitors
Documented hypersensitivity; narrow-angle glaucoma
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Exercise caution in patients (eg, elderly patients) where increased intraocular pressure may be present; can cause toxic anticholinergic systemic adverse effects (common in children, especially infants) but incidence rare when used sparingly; compressing lacrimal sac by digital pressure for 1-3 min, following application, may minimize systemic absorption
Peate WF. Work-related eye injuries and illnesses. Am Fam Physician. Apr 1 2007;75(7):1017-22. [Medline].
Carley F, Carley S. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Mydriatics in corneal abrasion. Emerg Med J. Jul 2001;18(4):273. [Medline].
Arbour JD, Brunette I, Boisjoly HM, Shi ZH, Dumas J, Guertin MC. Should we patch corneal erosions?. Arch Ophthalmol. Mar 1997;115(3):313-7. [Medline].
[Best Evidence] Turner A, Rabiu M. Patching for corneal abrasion. Cochrane Database Syst Rev. 2006;(2):CD004764. [Medline].
Augeri PA. Corneal foreign body removal and treatment. Optom Clin. 1991;1(4):59-70. [Medline].
Aziz MA, Rahman MA. Corneal foreign body--an occupational hazard. Mymensingh Med J. Jul 2004;13(2):174-6. [Medline].
Howell RM. Corneal abrasion. eMedicine Journal [serial online]. 2007;Available at http://www.emedicine.com/emerg/topic828.htm.
Hulbert MF. Efficacy of eyepad in corneal healing after corneal foreign body removal. Lancet. Mar 16 1991;337(8742):643. [Medline].
Jayamanne DG, Bell RW. Non-penetrating corneal foreign body injuries: factors affecting delay in rehabilitation of patients. J Accid Emerg Med. Sep 1994;11(3):195-7. [Medline].
Kaiser PK. A comparison of pressure patching versus no patching for corneal abrasions due to trauma or foreign body removal. Corneal Abrasion Patching Study Group. Ophthalmology. Dec 1995;102(12):1936-42. [Medline].
Kay-Wilson LG. Localisation of corneal foreign bodies. Br J Ophthalmol. Dec 1992;76(12):741-2. [Medline].
Newell SW. Management of corneal foreign bodies. Am Fam Physician. Feb 1985;31(2):149-56. [Medline].
Yang X. Removal of corneal foreign bodies that project into the anterior chamber: use of a suture needle. Am J Ophthalmol. Jun 2000;129(6):801-2. [Medline].
foreign material, cornea, foreign object, corneal abrasion, globe perforation, ocular trauma, ocular injury, rust ring
Mounir Bashour, MD, CM, FRCS(C), PhD, FACS, Assistant Professor of Ophthalmology, McGill University; Clinical Assistant Professor of Ophthalmology, Sherbrooke University; Medical Director, Cornea Laser and Lasik MD
Mounir Bashour, MD, CM, FRCS(C), PhD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American College of International Physicians, American College of Surgeons, American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Mechanical Engineers, American Society of Ophthalmic Plastic and Reconstructive Surgery, Biomedical Engineering Society, Canadian Medical Association, Canadian Ophthalmological Society, Contact Lens Association of Ophthalmologists, International College of Surgeons US Section, Ontario Medical Association, Quebec Medical Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.
Kilbourn Gordon III, MD, FACEP, Urgent Care Physician
Kilbourn Gordon III, MD, FACEP is a member of the following medical societies: American Academy of Ophthalmology and Wilderness Medical Society
Disclosure: Nothing to disclose.
Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.
Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Co-Chairman of the Cornea Service, Co-Chairman of Refractive Surgery Department, Wills Eye Institute
Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Eye Bank Association of America, Pennsylvania Medical Society, and Philadelphia County Medical Society
Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other
Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.
Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)